FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1838152093> ?p ?o ?g. }

• W1838152093 endingPage "728" @default.
• W1838152093 startingPage "718" @default.
• W1838152093 abstract "To evaluate the impact of concomitant methotrexate (MTX) on subcutaneous (SC) abatacept immunogenicity, and to assess safety and efficacy.This phase III, open-label study had a 4-month short-term (ST) period and an ongoing long-term extension (LTE) period. Rheumatoid arthritis patients were stratified to receive SC abatacept (125 mg/week) with (combination) or without MTX (monotherapy), with no intravenous loading dose; patients receiving monotherapy could add MTX in the LTE period. Immunogenicity (percentage of anti-abatacept antibody-positive patients) was assessed. ST and LTE period data are reported, including efficacy through LTE month 14 and safety through LTE month 20.Ninety-six of 100 enrolled patients completed the ST period; 3.9% (combination) and 4.1% of patients (monotherapy) developed transient immunogenicity, and no patients were antibody positive at month 4. Serious adverse events (SAEs) were reported in 3.9% (combination) and 6.1% of patients (monotherapy); 5.9% (combination) and 8.2% of patients (monotherapy) experienced SC injection reactions, and all were mild in intensity. Mean 28-joint Disease Activity Score (DAS28) changes were -1.67 (95% confidence interval [95% CI] -2.06, -1.28; combination) and -1.94 (95% CI -2.46, -1.42; monotherapy) at month 4. Ninety patients entered and were treated in the LTE period; 83.3% (75 of 90) remained ongoing at month 24. One LTE-treated patient (1.1%) developed immunogenicity, 14.4% of patients experienced SAEs, and no SC injection reactions were reported. For patients entering the LTE period, mean DAS28 changes from baseline were -1.84 (95% CI -2.23, -1.34; combination) and -2.86 (95% CI -3.46, -2.27; monotherapy) at month 18.SC abatacept did not elicit immunogenicity associated with loss of safety or efficacy, either with or without MTX." @default.
• W1838152093 created "2016-06-24" @default.
• W1838152093 creator A5003819213 @default.
• W1838152093 creator A5011826741 @default.
• W1838152093 creator A5018511764 @default.
• W1838152093 creator A5021255737 @default.
• W1838152093 creator A5026356361 @default.
• W1838152093 creator A5047184103 @default.
• W1838152093 creator A5066717773 @default.
• W1838152093 creator A5067509963 @default.
• W1838152093 creator A5082669130 @default.
• W1838152093 creator A5085301531 @default.
• W1838152093 creator A5086905906 @default.
• W1838152093 date "2013-04-23" @default.
• W1838152093 modified "2023-10-01" @default.
• W1838152093 title "Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study" @default.
• W1838152093 cites W1982176411 @default.
• W1838152093 cites W1992628263 @default.
• W1838152093 cites W1996472975 @default.
• W1838152093 cites W2015215846 @default.
• W1838152093 cites W2028514817 @default.
• W1838152093 cites W2055720024 @default.
• W1838152093 cites W2068315097 @default.
• W1838152093 cites W2078595150 @default.
• W1838152093 cites W2079404769 @default.
• W1838152093 cites W2081734937 @default.
• W1838152093 cites W2099559598 @default.
• W1838152093 cites W2100974168 @default.
• W1838152093 cites W2103310388 @default.
• W1838152093 cites W2115018403 @default.
• W1838152093 cites W2119046820 @default.
• W1838152093 cites W2119601740 @default.
• W1838152093 cites W2124670599 @default.
• W1838152093 cites W2126049604 @default.
• W1838152093 cites W2127742687 @default.
• W1838152093 cites W2149065814 @default.
• W1838152093 cites W2152348310 @default.
• W1838152093 cites W2152368246 @default.
• W1838152093 cites W2160699550 @default.
• W1838152093 cites W2171364167 @default.
• W1838152093 doi "https://doi.org/10.1002/acr.21876" @default.
• W1838152093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23097311" @default.
• W1838152093 hasPublicationYear "2013" @default.
• W1838152093 type Work @default.
• W1838152093 sameAs 1838152093 @default.
• W1838152093 citedByCount "68" @default.
• W1838152093 countsByYear W18381520932013 @default.
• W1838152093 countsByYear W18381520932014 @default.
• W1838152093 countsByYear W18381520932015 @default.
• W1838152093 countsByYear W18381520932016 @default.
• W1838152093 countsByYear W18381520932017 @default.
• W1838152093 countsByYear W18381520932018 @default.
• W1838152093 countsByYear W18381520932019 @default.
• W1838152093 countsByYear W18381520932020 @default.
• W1838152093 countsByYear W18381520932021 @default.
• W1838152093 countsByYear W18381520932022 @default.
• W1838152093 countsByYear W18381520932023 @default.
• W1838152093 crossrefType "journal-article" @default.
• W1838152093 hasAuthorship W1838152093A5003819213 @default.
• W1838152093 hasAuthorship W1838152093A5011826741 @default.
• W1838152093 hasAuthorship W1838152093A5018511764 @default.
• W1838152093 hasAuthorship W1838152093A5021255737 @default.
• W1838152093 hasAuthorship W1838152093A5026356361 @default.
• W1838152093 hasAuthorship W1838152093A5047184103 @default.
• W1838152093 hasAuthorship W1838152093A5066717773 @default.
• W1838152093 hasAuthorship W1838152093A5067509963 @default.
• W1838152093 hasAuthorship W1838152093A5082669130 @default.
• W1838152093 hasAuthorship W1838152093A5085301531 @default.
• W1838152093 hasAuthorship W1838152093A5086905906 @default.
• W1838152093 hasConcept C126322002 @default.
• W1838152093 hasConcept C141071460 @default.
• W1838152093 hasConcept C159654299 @default.
• W1838152093 hasConcept C197934379 @default.
• W1838152093 hasConcept C203014093 @default.
• W1838152093 hasConcept C2776999253 @default.
• W1838152093 hasConcept C2777575956 @default.
• W1838152093 hasConcept C2778715236 @default.
• W1838152093 hasConcept C2779338263 @default.
• W1838152093 hasConcept C2779384505 @default.
• W1838152093 hasConcept C2779605438 @default.
• W1838152093 hasConcept C2780653079 @default.
• W1838152093 hasConcept C2780868878 @default.
• W1838152093 hasConcept C2781059491 @default.
• W1838152093 hasConcept C71924100 @default.
• W1838152093 hasConceptScore W1838152093C126322002 @default.
• W1838152093 hasConceptScore W1838152093C141071460 @default.
• W1838152093 hasConceptScore W1838152093C159654299 @default.
• W1838152093 hasConceptScore W1838152093C197934379 @default.
• W1838152093 hasConceptScore W1838152093C203014093 @default.
• W1838152093 hasConceptScore W1838152093C2776999253 @default.
• W1838152093 hasConceptScore W1838152093C2777575956 @default.
• W1838152093 hasConceptScore W1838152093C2778715236 @default.
• W1838152093 hasConceptScore W1838152093C2779338263 @default.
• W1838152093 hasConceptScore W1838152093C2779384505 @default.
• W1838152093 hasConceptScore W1838152093C2779605438 @default.
• W1838152093 hasConceptScore W1838152093C2780653079 @default.
• W1838152093 hasConceptScore W1838152093C2780868878 @default.
• W1838152093 hasConceptScore W1838152093C2781059491 @default.

• next